These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravesical therapy for bladder cancer. Williams SK; Hoenig DM; Ghavamian R; Soloway M Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607 [TBL] [Abstract][Full Text] [Related]
3. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868 [TBL] [Abstract][Full Text] [Related]
4. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Huang Z; Liu H; Wang Y; Zhang C; Xu T Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272 [TBL] [Abstract][Full Text] [Related]
5. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618 [TBL] [Abstract][Full Text] [Related]
6. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Lamm D; Brausi M; O'Donnell MA; Witjes JA Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309 [TBL] [Abstract][Full Text] [Related]
7. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities. Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer. Ajili F; Darouiche A; Chebil M; Boubaker S Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613 [TBL] [Abstract][Full Text] [Related]
10. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. Laukhtina E; Abufaraj M; Al-Ani A; Ali MR; Mori K; Moschini M; Quhal F; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NC; Fajkovic H; Soria F; Enikeev D; Shariat SF; Eur Urol Focus; 2022 Mar; 8(2):447-456. PubMed ID: 33762203 [TBL] [Abstract][Full Text] [Related]
11. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. Chen S; Zhang N; Shao J; Wang X Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363 [TBL] [Abstract][Full Text] [Related]
12. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. Crijnen J; De Reijke TM Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950 [TBL] [Abstract][Full Text] [Related]
14. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study. Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096 [TBL] [Abstract][Full Text] [Related]
15. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Tan WS; Steinberg G; Witjes JA; Li R; Shariat SF; Roupret M; Babjuk M; Bivalacqua TJ; Psutka SP; Williams SB; Cookson MS; Palou J; Kamat AM Eur Urol Oncol; 2022 Oct; 5(5):505-516. PubMed ID: 35718695 [TBL] [Abstract][Full Text] [Related]
16. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate. Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries. Rahman ZA; Hidayatullah F; Lim J; Hakim L Arch Ital Urol Androl; 2024 Feb; 96(1):12154. PubMed ID: 38363237 [TBL] [Abstract][Full Text] [Related]
18. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411 [TBL] [Abstract][Full Text] [Related]
19. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. Barlow L; McKiernan J; Sawczuk I; Benson M BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012 [TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review. Saluja M; Gilling P Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]